

EGFL4 siRNA (h): sc-97270

BACKGROUND

EGFL4 (epidermal growth factor-like protein 4), also known as MEGF8 (multiple epidermal growth factor-like domains protein 8) or C19orf49, is a 2,845 amino acid single-pass type I membrane protein. EGFL4 contains 2 CUB domains, 5 EGF-like domains, 12 Kelch repeats, 4 laminin EGF-like domains and 7 PSI domains. Existing as two alternatively spliced isoforms, the gene encoding EGFL4 maps to human chromosome 19q13.2. Chromosome 19 consists of approximately 63 million bases, makes up over 2% of human genomic DNA, and is recognized for having the greatest gene density of the human chromosomes. It is the genetic home for a number of immunoglobulin superfamily members including the killer cell and leukocyte Ig-like receptors. Key genes for eye color and hair color also map to chromosome 19. Peutz-Jeghers syndrome, spinocerebellar ataxia type 6, the stroke disorder CADASIL, hypercholesterolemia and Insulin-dependent diabetes have been linked to chromosome 19.

REFERENCES

1. Zimmermann, W., Weber, B., Ortlieb, B., Rudert, F., Schempp, W., Fiebig, H.H., Shively, J.E., von Kleist, S. and Thompson, J.A. 1988. Chromosomal localization of the carcinoembryonic antigen gene family and differential expression in various tumors. *Cancer Res.* 48: 2550-2554.
2. Nakayama, M., Nakajima, D., Nagase, T., Nomura, N., Seki, N. and Ohara, O. 1998. Identification of high-molecular-weight proteins with multiple EGF-like motifs by motif-trap screening. *Genomics* 51: 27-34.
3. Scott, J.N., Metz, L., Hu, W.Y. and Hudon, M. 1999. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). *Can. J. Neurol. Sci.* 26: 311-312.
4. Trettel, F., Mantuano, E., Calabresi, V., Veneziano, L., Olsen, A.S., Georgescu, A., Gordon, L., Sabbadini, G., Frontali, M. and Jodice, C. 2000. A fine physical map of the CACNA1A gene region on 19p13.1-p13.2 chromosome. *Gene* 241: 45-50.
5. Buchet-Poyau, K., Mehenni, H., Radhakrishna, U. and Antonarakis, S.E. 2002. Search for the second Peutz-Jeghers syndrome locus: exclusion of the STK13, PRKCG, KLK10, and PSCD2 genes on chromosome 19 and the STK11IP gene on chromosome 2. *Cytogenet. Genome Res.* 97: 171-178.
6. Moodie, S.J., Norman, P.J., King, A.L., Fraser, J.S., Curtis, D., Ellis, H.J., Vaughan, R.W. and Ciclitira, P.J. 2002. Analysis of candidate genes on chromosome 19 in coeliac disease: an association study of the KIR and LILR gene clusters. *Eur. J. Immunogenet.* 29: 287-291.
7. Grimwood, J., Gordon, L.A., Olsen, A., Terry, A., Schmutz, J., Lamerdin, J., Hellsten, U., Goodstein, D., Couronne, O., Tran-Gyamfi, M., Aerts, A., Altherr, M., Ashworth, L., Bajorek, E., Black, S., et al. 2004. The DNA sequence and biology of human chromosome 19. *Nature* 428: 529-535.
8. Parham, P. 2005. Immunogenetics of killer cell immunoglobulin-like receptors. *Mol. Immunol.* 42: 459-462.
9. Brocke-Heidrich, K., Ge, B., Cvijic, H., Pfeifer, G., Löffler, D., Henze, C., McKeithan, T.W. and Horn, F. 2006. Bcl-3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. *Oncogene* 25: 7297-7304.

CHROMOSOMAL LOCATION

Genetic locus: MEGF8 (human) mapping to 19q13.2.

PRODUCT

EGFL4 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see EGFL4 shRNA Plasmid (h): sc-97270-SH and EGFL4 shRNA (h) Lentiviral Particles: sc-97270-V as alternate gene silencing products.

For independent verification of EGFL4 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-97270A, sc-97270B and sc-97270C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

EGFL4 siRNA (h) is recommended for the inhibition of EGFL4 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor EGFL4 gene expression knockdown using RT-PCR Primer: EGFL4 (h)-PR: sc-97270-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.